The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Baritaki, S., Suzuki, E., Umezawa, K., Spandidos, D. A., Berenson, J. R., Daniels‐Wells, T. R., Penichet, M. L., Jazirehi, A. R., Palladino, M. A., & Bonavida, B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6199 · Cited by 78
RetractedThe ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Feling, R. H., Buchanan, G. O., Mincer, T. J., Kauffman, C. A., Jensen, P. R., & Fenical, W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390115 · Cited by 1,057
The development of proteasome inhibitors as anticancer drugs
Adams, J. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00120-5 · Cited by 781
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694 · cited 3×
“), Abstract 1445 52 Chauhan, D. et al. (2008) Combination of a novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vivo synergistic cytotoxicity in multiple myeloma.”
InfluentialAntitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 678
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
Lee, A.-H., Iwakoshi, N. N., Anderson, K. C., & Glimcher, L. H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1334037100 · Cited by 601
The proteasome: structure, function, and role in the cell
ADAMS, J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00081-1 · Cited by 585
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Orlowski, R. Z., & Kuhn, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2218 · Cited by 578
Hershko, A. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401702 · Cited by 345
Tanaka, K., Ii, K., Ichihara, A., Waxman, L., & Goldberg, A. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66853-x · Cited by 324
Groll, M., Huber, R., & Potts, B. C. M. (2006) · Journal of the American Chemical Society · doi:10.1021/ja058320b · Cited by 312
Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Proteasome Inhibition Measurements: Clinical Application
Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.673 · Cited by 301
Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801329v · Cited by 272
Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., et al. (2008) · Blood · doi:10.1182/blood-2007-07-100651 · Cited by 252
Proteasome inhibitors: antitumor effects and beyond
Nencioni, A., Grünebach, F., Patrone, F., Ballestrero, A., & Brossart, P. (2007) · Leukemia · doi:10.1038/sj.leu.2404444 · Cited by 220
Miller, C. P., Ban, K., Dujka, M. E., McConkey, D. J., Munsell, M., Palladino, M., & Chandra, J. (2007) · Blood · doi:10.1182/blood-2006-03-013128 · Cited by 204
Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M. A., & Anderson, K. C. (2008) · Blood · doi:10.1182/blood-2007-08-105601 · Cited by 190
Paoluzzi, L., Gönen, M., Gardner, J. R., Mastrella, J., Yang, D., Holmlund, J., Sorensen, M., Leopold, L. H., Manova, K., Marcucci, G., et al. (2008) · Blood · doi:10.1182/blood-2007-12-129833 · Cited by 149
Dorsey, B., Iqbal, M., Chatterjee, S., Menta, E., Bernardini, R., Bernareggi, A., Cassarà, P., D'arasmo, G., Ferretti, E., Munari, S. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7010589 · Cited by 143
The potential of proteasome inhibitors in cancer therapy
Sterz, J., von Metzler, I., Hahne, J.-C., Lamottke, B., Rademacher, J., Heider, U., Terpos, E., & Sezer, O. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.6.879 · Cited by 135
Ahn, K. S., Sethi, G., Chao, T., Neuteboom, S., Chaturvedi, M. M., Palladino, M. A., Younes, A., & Aggarwal, B. B. (2007) · Blood · doi:10.1182/blood-2007-04-084996 · Cited by 124
Moreau, P., Coiteux, V., Hulin, C., Leleu, X. P., de Velde, H. J. V., Acharya, M. R., & Harousseau, J. (2008) · Haematologica · doi:10.3324/haematol.13285 · Cited by 121
Stapnes, C., Døskeland, A. P., Hatfield, K. J., Ersvær, E., Ryningen, A., Lorens, J. B., Gjertsen, B. T., & Bruserud, Ø. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06504.x · Cited by 118
Ruiz, S., Krupnik, Y. V., Keating, M. J., Chandra, J., Palladino, M. A., & McConkey, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0066 · Cited by 110
Bortezomib in the front-line treatment of multiple myeloma
Richardson, P. G. G., Mitsiades, C. S., Schlossman, R. L., Ghobrial, I. M., Hideshima, T., Munshi, N. C., & Anderson, K. C. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.7.1053 · Cited by 93
NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model
Cusack, J. C., Liu, R., Xia, L., Chao, T., Pien, C. S., Niu, W., Palombella, V. J., Neuteboom, S., & Palladino, M. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1151 · Cited by 89
Dual targeting of the proteasome regulates survival and homing in Waldenström macroglobulinemia
Roccaro, A. M., Leleu, X. P., Sacco, A., Jia, X., Melhem, M. R., Moreau, A., Ngo, H. T., Runnels, J. M., Azab, A., Azab, F., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120972 · Cited by 82
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Williamson, M. J., Blank, J. L., Bruzzese, F. J., Cao, Y., Daniels, J. S., Dick, L. R., LaButti, J. N., Mazzola, A. M., Patil, A. D., Reimer, C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0185 · Cited by 80
Self-citationTsueng, G., Teisan, S., & Lam, K. S. (2008) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-008-1358-9 · Cited by 39
The 19 S multicatalytic "prosome" proteinase is a constitutive enzyme in HeLa cells.
Hendil, K. B. (1988) · PubMed · Cited by 39
Csizmadia, V. (2007) · NeuroToxicology · doi:10.1016/j.neuro.2007.11.003 · Cited by 29
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation
O’Connor, O. A., & Czuczman, M. S. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802365033 · Cited by 19
Proteasome Inhibitor Associated Neuropathy Is Mechanism Based
Silverman, L. R., Csizmadia, V., Brewer, K., Simpson, C., & Alden, C. L. (2008) · Blood · doi:10.1182/blood.v112.11.2646.2646 · Cited by 9
Chauhan, D., Singh, A., Brahmandam, M., Bianchi, G., Podar, K., Hideshima, T., Munshi, N. C., Richardson, P. G. G., Palladino, M. A., & Anderson, K. C. (2008) · Blood · doi:10.1182/blood.v112.11.3662.3662 · Cited by 5
Huang, X., Bailey, K., Liberto, M. D., Parlati, F., Niesvizky, R., Demo, S. D., & Chen‐Kiang, S. (2008) · Blood · doi:10.1182/blood.v112.11.3670.3670 · Cited by 5
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., & Brownell, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3321 · Cited by 563
Self-citationProteolytic networks in cancer
Mason, S. D., & Joyce, J. A. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.12.002 · Cited by 552
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Arastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408
Metadata
- Authors
- Dick, L. R., & Fleming, P. E.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 15
- Issue
- 5-6
- Pages
- 243-249
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2091378741
- Cited by
- 273
- References
- 41
- FWCI
- 11.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.